Effect of Atorvastatin on Subclinical Atherosclerosis

• Status: Enrolling by invitation
• Trial end date: 2021-07-15
• Target enrollment: 0
• Participant gender: All

Summary

Statin administration is supposed to reduce subclinical atherosclerosis by decreasing LDL cholesterol levels, possibly via lipid-independent anti-inflammatory effect. Its pleiotropic properties also adding beneficial effect against CMV infection.

The investigators plan to study atorvastatin in virally- suppressed HIV-infected patients on stable ART with CMV seropositive and statin-naïve to evaluate the subclinical atherosclerosis changes assessed by carotid intima media thickness (CIMT).

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dr Cipto Mangunkusumo General Hospital
• Treatments: Atorvastatin

Criteria

Inclusion Criteria:

• Ages between 20 to 45 years old

• Using stable ART at least 1 year

• Positive IgG CMV

• Viral load HIV RNA <50 copies / ml

Exclusion Criteria:

• Undergoing hepatitis C DAA therapy

• Decompensated cirrhosis or acute liver failure

• History of coronary artery disease

• Diabetes mellitus

• History of of brain infection, epilepsy, stroke

• History of rhabdomyolysis or myopathy

• Pregnant or breastfeeding

• Severe depression

• Using statin therapy in the past 6 weeks

• History of statin hypersensitivity

• Framingham Risk Score above 10% within LDL ≥130

• Framingham Risk Score under 10% within LDL ≥160

• Out of Periodontitis Index (Upper right molars, top series, upper left molars, lower right molars, bottom series, lower left molars)